Leptoprol (Leuprorelin)

Leuprorelin is a synthetic GnRH agonist that first stimulates pituitary GnRH receptors, causing a brief rise in LH and FSH. Continued exposure leads to receptor down‑regulation, sharply reducing LH and FSH secretion and thereby lowering downstream testosterone or estrogen levels.

The appropriate dose of Leptoprol is set by the prescribing clinician based on the specific indication, patient age, disease stage, and individual response. Dosage regimens vary between oncology, gynecologic, and pediatric applications and are not standardized across all patients.

Leptoprol is generally contraindicated in pregnancy because it suppresses sex hormones essential for fetal development. Safety data for breastfeeding are limited, and the drug may be excreted in milk. Use is avoided unless the potential benefit outweighs the risk and under specialist guidance.

To order Leptoprol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Leptoprol (leuprorelin) is a long‑acting GnRH agonist administered as an implant, offering sustained hormone suppression with fewer dosing visits compared with daily injectable agonists. GnRH antagonists provide more rapid hormone suppression but often require more frequent administration. Choice depends on clinical goals, patient preference and safety considerations.

Leptoprol should be stored at room temperature, below 25 °C, in its original sealed packaging. Protect the implant from moisture, direct sunlight and extreme temperature fluctuations to maintain product stability until the time of implantation.

Leptoprol is provided as a sterile implant that is placed subcutaneously by a qualified healthcare professional. The implantation procedure is performed in a clinical setting, and the device releases leuprorelin continuously over a defined period, eliminating the need for daily injections.

Serious risks include loss of bone mineral density that can lead to osteoporosis, cardiovascular events such as myocardial infarction or stroke, and severe allergic reactions including anaphylaxis. Patients should be monitored regularly for these complications, especially during long‑term therapy.

Leptoprol should be avoided in individuals with known hypersensitivity to leuprorelin or any implant components, in patients with uncontrolled cardiovascular disease, severe liver impairment, or in women who are pregnant or planning pregnancy unless the benefits clearly outweigh the risks.